<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256085</url>
  </required_header>
  <id_info>
    <org_study_id>6818</org_study_id>
    <nct_id>NCT02256085</nct_id>
  </id_info>
  <brief_title>Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)</brief_title>
  <official_title>Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City University of New York, School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial (RCT) on the efficacy of repetitive Transcranial
      Magnetic Stimulation (rTMS) in the treatment of Depersonalization Disorder (DPD). TMS applies
      a magnetic field to the brain for a brief period of time. TMS is a procedure that involves 30
      minute-long daily sessions every weekday for a series of weeks. The investigators are testing
      whether TMS can treat Depersonalization Disorder (DPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a research trial of an outpatient, non-medication, non-invasive investigational
      treatment called Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive tool for the
      study of the human brain that has been approved by the FDA for use in depression, but it is
      also being investigated as a potential therapeutic agent for other symptoms, such as those
      seen in Depersonalization Disorder (DPD).

      TMS applies a magnetic field to the brain for a brief period of time. TMS is a procedure that
      involves 30 minute-long daily sessions every weekday for a series of weeks. The investigators
      are testing whether TMS can treat Depersonalization Disorder (DPD).

      In this trial, 32 adult outpatients with DPD, that have been only partially responsive to
      conventional therapies, will be treated with active or sham low frequency (1 Hz) rTMS applied
      to the right temporo-parietal junction (TPJ) daily for up to six weeks.

      DPD symptoms will be monitored through weekly self-report questionnaires as well clinical
      ratings with a doctor.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cambridge Depersonalization Scale (CDS)</measure>
    <time_frame>Change from baseline after 6 weeks of active rTMS</time_frame>
    <description>The outcome of subjects randomized to active rTMS in phase 1 will be assessed as the change from baseline after 6 weeks of daily rTMS (week 6 assessment). Subjects randomized to receive sham in phase 1 will be assessed at baseline and week 6, but the primary method of assessing improvement will be the change between the baseline and week 12 scores (i.e. after receiving 6 weeks of active rTMS).
Scale item number: 29 Item score range: Frequency: 0 - 4, Duration: 0-5 Minimum CDS score: 0 Maximum CDS score: 261
Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement (assessed by CGI-S)</measure>
    <time_frame>Change from baseline after 6 weeks of active rTMS</time_frame>
    <description>The outcome of subjects randomized to active rTMS in phase 1 will be assessed as the change from baseline after 6 weeks of daily rTMS (week 6 assessment). Subjects randomized to receive sham in phase 1 will be assessed at baseline and week 6, but the primary method of assessing improvement will be the change between the baseline and week 12 scores (i.e. after receiving 6 weeks of active rTMS).
Minimum CGI-S score: 1 Maximum CGI-S score: 7
Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.
Patients will be classified as responders with a CGI-S = 1 or 2; and partial responders CGI-S = 3.
= Normal, not at all ill
= Borderline mentally ill
= Mildly ill
= Moderately ill
= Markedly ill
= Severely ill
= Among the most extremely ill patients</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Depersonalization Disorder</condition>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Daily rTMS with Sham coil
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily rTMS with Active coil
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Daily rTMS with Active coil
30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Daily rTMS with Active coil</intervention_name>
    <description>rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks</description>
    <arm_group_label>Active rTMS</arm_group_label>
    <other_name>Magstim, Magstim Rapid, Magstim Rapid2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Daily rTMS with Sham coil</intervention_name>
    <description>rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks</description>
    <arm_group_label>Sham rTMS</arm_group_label>
    <other_name>Magstim, Magstim Rapid, Magstim Rapid2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Open Label Daily rTMS with Active coil</intervention_name>
    <description>rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks</description>
    <arm_group_label>Open Active rTMS</arm_group_label>
    <other_name>Magstim, Magstim Rapid, Magstim Rapid2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients, 18 to 70 years of age.

          -  Primary diagnosis of Depersonalization Disorder.

          -  Duration of the index episode of at least a year.

          -  Patients currently on DPD medication must be at the same stable dose(s) at least 2
             months and be to continue at the same dose(s) through the duration of the study.

          -  Patients must continue to be under the care of their treating psychiatrist who will be
             writing prescriptions for concomitant medications through the duration of the study.

          -  Capable and willing to provide informed consent

        Exclusion Criteria:

          -  Individuals diagnosed with current Major Depressive Disorder or Panic Disorder.

          -  Individuals diagnosed with the following conditions: Bipolar Disorder (lifetime), any
             Psychotic Disorder (lifetime), History of substance abuse or dependence within the
             past yea (except nicotine and caffeine).

          -  Individuals with a neurological disorder including, but not limited to: brain lesion;
             history of seizures; history of cerebrovascular accident; history of stroke; TIA,
             cerebral aneurysm, Dementia; Parkinson's Disease; Huntington's chorea; Multiple
             Sclerosis.

          -  Increased risk of seizure for any reason, including prior head trauma with loss of
             consciousness for 5 minutes or more

          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable
             cardiac disease.

          -  Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants,
             or electrodes) or any other metal object within or near the head, excluding the mouth,
             that cannot be safely removed.

          -  History of treatment with rTMS therapy for any disorder.

          -  If participating in psychotherapy, must have been in stable treatment for at least
             three months prior to entry into the study, with no anticipation of change in
             frequency of therapeutic sessions, or the therapeutic focus over the duration of the
             rTMS trial.

          -  Known or suspected pregnancy.

          -  Women who are breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Mantovani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUNY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Javitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sophie Davis School of Biomedical Education, City University of New York (CUNY)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute, Experimental Therapeutics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://columbiapsychiatry.org/research/Experimental-Therapeutics</url>
    <description>Division of Experimental Therapeutics (NYSPI) website</description>
  </link>
  <link>
    <url>http://columbiapsychiatry.org/</url>
    <description>Department of Psychiatry, Columbia University Medical Center</description>
  </link>
  <link>
    <url>http://www.ccny.cuny.edu/sophiedavis/physpharmandneuro.cfm</url>
    <description>Sophie Davis School of Biomedical Education, City University of New York (CUNY)</description>
  </link>
  <link>
    <url>http://www.nimh.nih.gov/index.shtml</url>
    <description>National Institute of Mental Health</description>
  </link>
  <reference>
    <citation>Blanke O, Mohr C, Michel CM, Pascual-Leone A, Brugger P, Seeck M, Landis T, Thut G. Linking out-of-body experience and self processing to mental own-body imagery at the temporoparietal junction. J Neurosci. 2005 Jan 19;25(3):550-7.</citation>
    <PMID>15659590</PMID>
  </reference>
  <reference>
    <citation>Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology. 1997 May;48(5):1398-403.</citation>
    <PMID>9153480</PMID>
  </reference>
  <reference>
    <citation>Hunter EC, Baker D, Phillips ML, Sierra M, David AS. Cognitive-behaviour therapy for depersonalisation disorder: an open study. Behav Res Ther. 2005 Sep;43(9):1121-30.</citation>
    <PMID>16005701</PMID>
  </reference>
  <reference>
    <citation>Jim√©nez-Genchi AM. Repetitive transcranial magnetic stimulation improves depersonalization: a case report. CNS Spectr. 2004 May;9(5):375-6.</citation>
    <PMID>15115950</PMID>
  </reference>
  <reference>
    <citation>Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol. 2003 Mar;17(1):103-5.</citation>
    <PMID>12680746</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Guralnik O, Hazlett EA, Spiegel-Cohen J, Hollander E, Buchsbaum MS. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry. 2000 Nov;157(11):1782-8.</citation>
    <PMID>11058475</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry. 2004 Jul;185:31-6.</citation>
    <PMID>15231553</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol. 2005 Jun;25(3):267-70.</citation>
    <PMID>15876908</PMID>
  </reference>
  <reference>
    <citation>Simeon D. Depersonalisation disorder: a contemporary overview. CNS Drugs. 2004;18(6):343-54. Review.</citation>
    <PMID>15089102</PMID>
  </reference>
  <reference>
    <citation>Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16.</citation>
    <PMID>9474057</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-39. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. Review.</citation>
    <PMID>19833552</PMID>
  </reference>
  <reference>
    <citation>Christopeit M, Simeon D, Urban N, Gowatsky J, Lisanby SH, Mantovani A. Effects of repetitive transcranial magnetic stimulation (rTMS) on specific symptom clusters in depersonalization disorder (DPD). Brain Stimul. 2014 Jan-Feb;7(1):141-3. doi: 10.1016/j.brs.2013.07.006. Epub 2013 Aug 6.</citation>
    <PMID>23941986</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dissociative</keyword>
  <keyword>Dissociation</keyword>
  <keyword>Depersonalization</keyword>
  <keyword>Depersonalization Disorder</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>TMS</keyword>
  <keyword>DPD</keyword>
  <keyword>rTMS</keyword>
  <keyword>Behavioral Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depersonalization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

